Endocrine therapy, resistance, and dormancy

This part of the ER-positive section gathers the pages that sit closest to treatment pressure, survival under therapy, and late escape.

Use these pages together when the real question is not only which drug comes next, but what surviving cells may be doing during treatment.

Start here

• ER-Positive / HER2-Negative
  Main hub for the wider ER-positive, HER2-negative section.

• CDK4/6 Options and Supplement Considerations
  Practical comparison of palbociclib, ribociclib, and abemaciclib, including monitoring and supplement-fit questions.

• Autophagy Escape in ER-Positive Breast Cancer
  Why autophagy, mTOR pressure, glycolysis, and hydroxychloroquine keep coming up in this subtype.

• Autophagy and Senescence in Antiestrogen Resistance
  Short, paced guide to the 2024 review on autophagy, reversible senescence, and acquired endocrine resistance.

• Dormancy, Senescence, Autophagy, and Trial Context in ER+ Disease
  Deeper guide to dormant cells, autophagy trials, and the treatment-by-treatment lens in ER-positive disease.

• Endocrine Therapy, Stable Disease, and Dormancy in ER-Positive Breast Cancer
  Why ER-positive disease can stay quiet for long periods, and why late reactivation still happens.

• Slow-Growing ER+ Breast Cancer Cells and How Rac-1 and The IGF Axis Supports Relapse
  New 2026 paper summary on slow-cycling, senescent-like ER+ survivors, Rac1 signalling, and the IGF-axis escape route.

• AI Resistance and the 4-OHE1/E2 Pathway
  Estrogen-metabolism and resistance-handling questions that come up around aromatase-inhibitor progression.

• FGFR1 Amplification in ER+ Breast Cancer
  Why FGFR1 matters in luminal-B-like biology, endocrine resistance, and fluctuating ctDNA results.

• Blood Biopsy Trial — Getting Ahead of Treatment Resistance
  How ctDNA and early ESR1 tracking may help identify resistance sooner.

• Diet and Gut Health May Shape Immunotherapy Response
  Histidine, microbiome context, and T-cell metabolism in checkpoint-inhibitor response.